‘Use it again!’: retherapy with bendamustine in indolent B-cell lymphoproliferative disorders

References

• Ozegowski W, Krebs D. IMET 3393, (-[1-methyl- 5-bis-(-chloroethyl)-amino-benzimidazolyl-(2)]-butyric) acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds. Zbl. Pharm. 110, 1013–1019 (1971).
   Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. 27(26), 4378–4384 (2009).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a Phase II multicenter, single-agent study. J. Clin. Oncol. 26(2), 204–210 (2008).
   PubMed Web of Science ®Google Scholar
• Köppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone – a new effective treatment for advanced chronic lymphocytic leukaemia: results of a Phase I/II study. Leuk. Lymphoma 45(5), 911–913 (2004).
   PubMed Web of Science ®Google Scholar
• Köppler H, Fuss H, Hurtz HJ et al.; GCLLSG. Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre Phase II study of the German CLL Study Group (GCLLSG). Br. J. Haematol. 158(2), 238–241 (2012).
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol. 23(15), 3383–3389 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 26(27), 4473–4479 (2008).
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol. 23(15), 3383–3389 (2005).
   PubMed Web of Science ®Google Scholar
• Weide R, Hess G, Köppler H et al.; German Low Grade Lymphoma Study Group. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter Phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk. Lymphoma 48(7), 1299–1306 (2007).
   PubMed Web of Science ®Google Scholar
• Weide R, Mergenthaler U, Friesenhahn V et al. Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia. Leuk. Lymphoma 50(9), 1468–1474 (2009).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS et al. Multicenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 24(30), 4867–4874 (2006).
   PubMed Web of Science ®Google Scholar
• Goy A, Bernstein SH, Kahl BS et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter Phase II PINNACLE study. Ann. Oncol. 20(3), 520–525 (2009).
   PubMed Web of Science ®Google Scholar
• Matous J, Letzer J, Rosen P et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: dose-finding results of the VERTICAL study. J. Clin. Oncol. 27, 15 (2009).
   Google Scholar
• Fischer K, Cramer P, Busch R et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 29(26), 3559–3566 (2011).
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 30(26), 3209–3216 (2012).
   PubMed Web of Science ®Google Scholar
• Weide R, Feiten S, Friesenhahn V et al. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leuk. Lymphoma doi:10.3109/10428194.2012.747679 (2012) (Epub ahead of print).
   PubMedGoogle Scholar